Sejun Park

19PUBLICATIONS
66CO-AUTHORS
ChemotherapyPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 22, 2026
Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial.

|Nov 27, 2025
Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications.

Dongwoo Cho, Kabsoo Shin, Tae Ho Hong

|Nov 13, 2025
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon

|Oct 29, 2025
Multiple Primary Cancers as an Independent Criterion for Germline Testing: Comparison with Guideline-Based Criteria.

Kabsoo Shin, Hoon Seok Kim, Hee Yeon Lee

|Oct 16, 2025
Dynamic Integrative Immune Profiling Reveals Early Biomarkers of Response and Prognosis in Advanced Gastric Cancer Treated with Nivolumab Plus Chemotherapy.

Hyunho Kim, Kabsoo Shin, Se Jun Park

|Jun 13, 2025
Skeletal Muscle Density as a Predictive Marker for Pathologic Complete Response in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemoimmunotherapy.

Han Song Mun, Sung Hun Kim, Jieun Lee

Pageof 4

Frequent Collaborators

14 joint publications

MyungAh Lee

9 joint publications

Kabsoo Shin

6 joint publications

Younghoon Kim

5 joint publications

Tae Ho Hong